GETI.B

182.9

-3.18%↓

EKTA.B

52.9

-1.31%↓

ARJOB

24.1

-1.79%↓

MSON.B

12.15

+2.97%↑

GETI.B

182.9

-3.18%↓

EKTA.B

52.9

-1.31%↓

ARJOB

24.1

-1.79%↓

MSON.B

12.15

+2.97%↑

GETI.B

182.9

-3.18%↓

EKTA.B

52.9

-1.31%↓

ARJOB

24.1

-1.79%↓

MSON.B

12.15

+2.97%↑

GETI.B

182.9

-3.18%↓

EKTA.B

52.9

-1.31%↓

ARJOB

24.1

-1.79%↓

MSON.B

12.15

+2.97%↑

GETI.B

182.9

-3.18%↓

EKTA.B

52.9

-1.31%↓

ARJOB

24.1

-1.79%↓

MSON.B

12.15

+2.97%↑

Inicio・Lista de Acciones・Vivesto AB

Vivesto AB

Cerrado

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave
By Trading Economics
Ingresos	-1.9M -9.1M
BPA	-0.015
Empleados	4
EBITDA	-1.8M -8.9M

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	38M 90M
Apertura anterior	0
Cierre anterior	0

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 23:08 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 23:07 UTC

Ganancias

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:20 UTC

Ganancias

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 abr 2026, 23:27 UTC

Charlas de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 abr 2026, 23:22 UTC

Ganancias

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 abr 2026, 23:20 UTC

Charlas de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 abr 2026, 22:52 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:33 UTC

Ganancias

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 abr 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 abr 2026, 22:05 UTC

Ganancias

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 21:57 UTC

Ganancias

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 abr 2026, 21:55 UTC

Ganancias

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 abr 2026, 21:53 UTC

Ganancias

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.